Titan Biotech Ltd
BSE:TITANBIOStandalone figures
| Ratio | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||
| Gross margin % | — | — | 56.5% | 52.3% | 51.5% | 53.9% | 53.6% | 53.3% |
| EBITDA margin % | 12.7% | 15.6% | 34.1% | 25.2% | 20.5% | 20.9% | 16.3% | 18.7% |
| EBIT margin % | 9.9% | 13.1% | 32.4% | 23.3% | 18.7% | 18.9% | 13.6% | 16.3% |
| PAT margin % | 5.3% | 8.9% | 23.5% | 17.6% | 14.6% | 14.4% | 11.7% | 13.3% |
| Working capital | ||||||||
| Receivable days | — | — | 48 | 48 | 53 | 42 | 44 | 40 |
| Inventory days | — | — | 184 | 215 | 189 | 220 | 255 | 212 |
| Payable days | — | — | 18 | 26 | 29 | 16 | 26 | 32 |
| NWC days | — | — | 213 | 237 | 213 | 245 | 273 | 220 |
| Leverage | ||||||||
| Current ratio | — | — | 3.41 | 3.85 | 3.36 | 3.71 | 4.46 | 3.28 |
| Debt to EBITDA | — | — | 0.18 | 0.19 | 0.24 | 0.21 | 0.08 | 0.1 |
| Debt to equity | — | — | 0.11 | 0.07 | 0.07 | 0.06 | 0.01 | 0.02 |
| Interest coverage | 3.1 | 5.2 | 31.5 | 38.1 | 38.5 | 27.9 | 31.5 | 42.9 |
| Asset turnover | — | — | 1.42 | 1.15 | 1.1 | 1.08 | 0.94 | 1.01 |
| Return ratios | ||||||||
| Return on assets % | — | — | 33.4% | 20.2% | 16.1% | 15.6% | 11% | 13.5% |
| Return on capital employed % | — | — | 56.4% | 36.6% | 28.6% | 26.9% | 17.9% | 24% |
| Return on equity % | — | — | 43.7% | 25.1% | 19.8% | 18.4% | 12.6% | 16.1% |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.